Marine-Derived Drugs in Alzheimer's: Modest, Inconsistent Cognitive Signals
This Bayesian network meta-analysis quantifies the comparative cognitive efficacy and short-term safety of five marine-derived agents in Alzheimer's disease, informing how pharmacists interpret emerging naturally sourced therapeutics against a backdrop of largely negative confirmatory data.
📅 Journal publication: 2026(online Aug 8, 2026)·Last updated: Aug 11, 2026
Marine-derived drugs show potential but varied cognitive effects in Alzheimer's.
Marine-derived drugs are being explored for cognitive benefits in Alzheimer's disease (AD), but comparative efficacy and safety require clarification. GV-971 improved ADAS-Cog scores (MD -1.85, 95% CI -2.89 to -0.82), and rifampicin showed potential MMSE benefits (MD 1.90, 95% CI 0.25 to 3.56), but outcomes varied. While some marine drugs show cognitive improvement in specific measures, none are consistently superior; further large RCTs are needed to determine optimal treatments. Marine-derived drugs show potential but inconsistent cognitive benefits in Alzheimer's disease.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Song Z, Xie Y, Zhu H, Li J, Yang C, Guo Y, Nong X, Zhu Z, Chen Z, Wang Z
Citation:Song Z, Xie Y, Zhu H, et al. Evaluating the cognitive efficacy of marine-derived drugs in Alzheimer's disease: A systematic review and Bayesian network meta-analysis. Therapeutic advances in neurological disorders. 2026;19:17562864261476868. doi:10.1177/17562864261476868